Drug Profile
Research programme: metabolic disorder therapeutics - Acceleron
Alternative Names: ACE 07X; ACE-06X; ACE-435Latest Information Update: 01 Dec 2021
Price :
$50
*
At a glance
- Originator Acceleron Pharma
- Class Proteins
- Mechanism of Action Transforming growth factor beta inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Metabolic disorders
Most Recent Events
- 22 Nov 2021 Acceleron Pharma has been acquired by Merck & Co
- 16 Jul 2016 No recent reports of development identified for preclinical development in Metabolic-disorders in USA
- 27 Jan 2010 Preclinical trials in Metabolic disorders in USA (unspecified route)